| Similar Articles |
|---|
 |
Bio-IT World
March 8, 2005
John Russell |
Entelos' Lofty Aspirations This is an interesting period for systems biology's wing of predictive biology companies. The label's luster is fading, but buoyed by pharma's growing interest, they are trying to figure out how to grow.   |
Chemistry World
March 12, 2007 |
Akzo Nobel Sells Medicines Business to Schering Plough US drug giant Schering-Plough is to buy Dutch chemical company Akzo Nobel's pharmaceuticals and animal health business, Organon BioSciences, for 11 billion euros. |
Bio-IT World
August 18, 2004
Mark D. Uehling |
I, Virtual Patient Along with a software company specializing in modeling diseases on the computer, Roche Diagnostics is working on creating a new biomarker for diabetes that could be reduced to a simple blood test. |
Bio-IT World
June 17, 2004
John Russell |
Systems Biology - Now Leaving on Track 1 Entelos, a leader in predictive biosimulation, partners with pharmaceutical and biotech organizations worldwide to develop effective new treatments for disease. Michael French, chief business officer at Entelos, explains what powers the systems biology engine. |
Bio-IT World
May 19, 2004
John Russell |
Seeing the Forest and the Trees A tiny clearing in the fog of systems biology. |
Bio-IT World
February 2006
John Russell |
Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems. |
Bio-IT World
November 12, 2002
Michael Goldman |
A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico? |
Bio-IT World
September 2006
John Russell |
Predicting the Future of Systems Biology Buoyed by promising results from a recent collaboration with Pfizer on drug-induced vascular injury, Keith Elliston, CEO of modeling and biosimulation specialist Genstruct, offers a candid view of industry's flirtation with systems biology and the future prospects for the field. |
The Motley Fool
August 7, 2007
Brian Orelli |
Financing Your Acquisition Schering-Plough is one step closer to financing its $14 billion acquisition of the Organon BioSciences unit of Akzo Nobel, by making an official stock offering. |
The Motley Fool
March 2, 2010
Brian Orelli |
Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off. |
The Motley Fool
November 27, 2007
Brian Orelli |
Ploughing Into Acquisition Rewards Schering-Plough reaps its first New Drug Application from its purchase of Organon. Investors, take note. |
BusinessWeek
May 14, 2007
Arlene Weintraub |
Schering-Plough Climbs Out Of Its Sickbed Fred Hassan said getting drugmaker Schering-Plough on its feet might take years. Investors are beginning to see the virtues of patience |
Bio-IT World
August 18, 2004 |
Project Summaries Drug Discovery and Development: Ace BioSciences... Compugen... Entelos/Organon... Iconix Pharmaceuticals... Johnson & Johnson Pharmaceutical Research & Development... Laboratoire Kastler Brossel ... etc. |
Bio-IT World
October 2006
John Russell |
Entelos Makes Post IPO Report After netting $16.6 million in a public offering on London's Alternative Investment Market last April, biosimulator Entelos released interim six-month results. |
The Motley Fool
October 23, 2007
Brian Orelli |
Schering Ploughed Down Investors punish the pharmaceutical company when it misses Wall Street expectations following 11 consecutive quarters of double-digit sales growth. |
Scientific American
June 2008
Melinda Wenner |
Jeremy Nicholson's Gut Instincts: Researching Intestinal Bacteria The body and its intestinal flora produce chemicals with hidden health information, Jeremy Nicholson has found. Someday treating disease may mean treating those bacteria. |
The Motley Fool
November 20, 2009
Brian Orelli |
This Baby Is a Nice Addition A month into an acquisition, and Merck already sees a benefit. |
Bio-IT World
May 2006
Kevin Davies |
Trailblazers Test Public Markets Three companies in postgenomic fields are going public. Infinity Pharmaceuticals, Perlegen Sciences, and Entelos announced they would be entering the public markets by means of merger, IPO, and institutional offering. |
Chemistry World
April 21, 2008
Pete Mitchel |
The hunt for metabolic biomarkers In the largest metabonomics study ever carried out, researchers have discovered strong correlations between individuals' blood pressure and the levels of certain metabolites in their urine. |
Bio-IT World
December 15, 2003
Mark D. Uehling |
Model Patient Despite the FDA's new support for computational modeling, the pharmaceutical industry remains cautious about simulating clinical trials. |
